The objectives of this prospective observational study were to estimate the frequency of patients who reported an impact of chemotherapy-induced nausea and vomiting (CINV) on their daily life and to evaluate the determinants of such an impact.
Materials and methodsAdult cancer patients at seven Italian oncology centers who were receiving cisplatin-containing regimens reported incidence and intensity of CINV for eight consecutive days in a diary and completed a Functional Living Index for Emesis (FLIE) questionnaire.
Main resultsOverall, 34% of patients reported vomiting and 62% reported nausea after chemotherapy. On days 1 to 5 after receiving chemotherapy, 67% of patients who had at least one emetic episode and 77% of those who suffered from at least mild nausea experienced an impact on their daily activities as measured on the FLIE questionnaire. More than 90% of all patients with both acute and delayed nausea or vomiting reported an impact on their daily life. Both acute and delayed vomiting contributed in similar measure to impact daily life; however, the importance of delayed nausea was greater than that of acute nausea.
ConclusionsDespite antiemetic prophylaxis, CINV is still prevalent and often impacts the daily life of patients in Italy, especially in the delayed phase. The duration more than the severity seems to be responsible for the impact of CINV on the patients’ daily lives.
This is a preview of subscription content, log in via an institution to check access.
Access this article Subscribe and saveSpringer+ Basic
€34.99 /Month
Price includes VAT (Germany)
Instant access to the full article PDF.
Similar content being viewed by others Explore related subjectsDiscover the latest articles and news from researchers in related subjects, suggested using machine learning. ReferencesAapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13:117–121
Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 9:811–819
Ballatori E (2001) Unsolved problems in evaluating the quality of life of cancer patients. Ann Oncol 12(Suppl 3):S11–S13
Ballatori E, Roila F (2003) Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 1:46–58
de Boer-Dennert M, de Wit R, Schmitz PI et al (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061
Fabi A, Barduagni M, Lauro S et al (2003) Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 11:156–161
Glaus A, Knipping C, Morant R et al (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708–715
Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971–2994
Griffin AM, Butow PN, Coates AS et al (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195
Grunberg SM, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268
Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13:80–84
Italian Group for Evaluation of Outcomes in Oncology (IGEO) (1999) Patient compliance with quality of life questionnaires. Tumori 85:92–95
Kris MG, Hesketh PJ, Herrstedt J et al (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13:85–96
Lindley CM, Hirsch JD, O’Neill CV et al (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340
Martin AR, Pearson JD, Cai B et al (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index—Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522–527
Osoba D, Zee B, Warr D et al (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5:307–313
Roila F, Donati D, Tamberi S et al (2002) Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 10:88–95
The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20–28
The Italian Group For Antiemetic Research (1992) Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 340:96–99
The Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1–5
The Italian Group of Antiemetic Research (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805–810
The Italian Group for Antiemetic Research (1997) Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 15:124–130
The Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554–1559
Uyl-de Groot CA, Wait S, Buijt I (2000) Economics and health-related quality of life in antiemetic therapy: recommendations for trial design. Eur J Cancer 36:1522–1535
This study was funded by Merck and Company, Incorporated, Whitehouse Station, NJ, USA. Writing assistance was provided by Elizabeth V. Hillyer, DVM, ELS, with support from Merck and Company, Incorporated.
Author information Authors and AffiliationsMedical Statistics Unit, Department of Internal Medicine and Public Health, University of L’Aquila, Via Pillino 2, 63030, Spinetoli (AP), Italy
Enzo Ballatori
Medical Oncology Division, Policlinic Hospital, Perugia, Italy
Fausto Roila & Maura Betti
Department of Prevention, ASUR Marche, ZT 13, Ascoli Piceno, Italy
Benedetta Ruggeri
Division of Medical Oncology, Department of Oncology, University of Pisa, Pisa, Italy
Samanta Sarti
Division of Medical Oncology, Ospedale Civile, Sassari, Italy
Giancarla Soru
Oncology Department, Ospedale Civile, Lugo di Ravenna, Italy
Giorgio Cruciani
Medical Oncology B, National Cancer Institute, Naples, Italy
Massimo Di Maio
Department of Oncology, San Carlo Borromeo Hospital, Milan, Italy
Biffi Andrea
Outcomes Research, Merck and Company, Incorporated, Whitehouse Station, NJ, USA
Robert R. Deuson
Correspondence to Enzo Ballatori.
About this article Cite this articleBallatori, E., Roila, F., Ruggeri, B. et al. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15, 179–185 (2007). https://doi.org/10.1007/s00520-006-0109-7
Received: 19 February 2006
Accepted: 14 June 2006
Published: 29 August 2006
Issue Date: February 2007
DOI: https://doi.org/10.1007/s00520-006-0109-7
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4